A phase Ia/b study (NCT04720313) of a novel anti-BCMA CAR T cell therapy developed at Hadassah Medical Center was the first prospective trial to include patients with AL amyloidosis and reported on the safety and feasibility of this approach (34). The gene discussed is TNFRSF17; the disease is AL amyloidosis.